AngioDynamics Valuation Multiples

Discover AngioDynamics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like IBA Group, NeuroPace, Mesa Laboratories, Sofwave Medical and more.

AngioDynamics Overview

About AngioDynamics

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.


Founded

1992

HQ

United States

Employees

675

Financials (LTM)

Revenue: $322M
EBITDA: $18M

EV

$519M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

AngioDynamics Financials

AngioDynamics reported last 12-month revenue of $322M and EBITDA of $18M.

In the same LTM period, AngioDynamics generated $176M in gross profit, $18M in EBITDA, and had net loss of ($7M).

Revenue (LTM)


AngioDynamics P&L

In the most recent fiscal year, AngioDynamics reported revenue of $320M and EBITDA of $18M.

AngioDynamics is unprofitable as of last fiscal year, with gross margin of 55%, EBITDA margin of 6%, and net margin of (2%).

See analyst estimates for AngioDynamics
LTMLast FY202320242025202620272028
Revenue$322M$320M$318M$297M$309M
Gross Profit$176M$175M$163M$156M$168M
Gross Margin55%55%51%53%54%
EBITDA$18M$18M($12M)($2M)$1M
EBITDA Margin5%6%(4%)(1%)0%
EBIT Margin(12%)(7%)(9%)(9%)(7%)
Net Profit($7M)($6M)($129M)($97M)($36M)
Net Margin(2%)(2%)(41%)(33%)(12%)

Financial data powered by Morningstar, Inc.

AngioDynamics Stock Performance

AngioDynamics has current market cap of $558M, and enterprise value of $519M.

Market Cap Evolution


AngioDynamics' stock price is $13.51.

AngioDynamics share price increased by 3.8% in the last 30 days, and by 52.5% in the last year.

AngioDynamics has an EPS (earnings per share) of $-0.15.

See more trading valuation data for AngioDynamics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$519M$558M0.0%3.8%23.4%52.5%$-0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

AngioDynamics Valuation Multiples

AngioDynamics trades at 1.6x EV/Revenue multiple, and 29.4x EV/EBITDA.

See NTM and 2027E valuation multiples for AngioDynamics

EV / Revenue (LTM)


AngioDynamics Financial Valuation Multiples

As of July 19, 2026, AngioDynamics has market cap of $558M and EV of $519M.

AngioDynamics has a P/E ratio of (76.6x).

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.6x1.6x1.7x1.7x
EV/EBITDA29.4x28.5x(42.3x)n/mn/m
EV/EBIT(13.6x)(23.2x)(18.8x)(18.4x)(22.5x)
EV/Gross Profit2.9x3.0x3.2x3.3x3.1x
P/E(76.6x)(90.4x)(4.3x)(5.8x)(15.7x)
EV/FCF-n/m(24.0x)(22.9x)(89.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified AngioDynamics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

AngioDynamics Margins & Growth Rates

AngioDynamics grew revenue by 5% but EBITDA decreased by 22% in the last fiscal year.

In the most recent fiscal year, AngioDynamics reported gross margin of 55%, EBITDA margin of 6%, and net margin of (2%).

See estimated margins and future growth rates for AngioDynamics

AngioDynamics Margins

Last FY202420252026202720282029
Gross Margin55%53%54%54%
EBITDA Margin6%(1%)0%3%
EBIT Margin(7%)(9%)(7%)(8%)
Net Margin(2%)(33%)(12%)(7%)
FCF Margin0%(8%)(2%)0%

AngioDynamics Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%(7%)4%7%
Gross Profit Growth5%(4%)7%7%
EBITDA Growth(22%)(87%)(171%)680%
EBIT Growth23%2%(18%)10%
Net Profit Growth135%(25%)(63%)(33%)
FCF Growth-5%(74%)(109%)

Data powered by FactSet, Inc. and Morningstar, Inc.

AngioDynamics Operational KPIs

AngioDynamics' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

AngioDynamics' Rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

AngioDynamics' Rule of X is 20% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for AngioDynamics
LTMLast FY202320242025202620272028
Rule of 4011%10%---
Bessemer Rule of X19%20%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.3M---
S&M Expenses to Revenue35%35%32%35%35%
G&A Expenses to Revenue14%14%13%14%14%
R&D Expenses to Revenue9%9%10%10%9%
Opex to Revenue-62%60%62%62%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

AngioDynamics Competitors

AngioDynamics competitors include IBA Group, NeuroPace, Mesa Laboratories, Sofwave Medical, Myriad Genetics, Japan Lifeline, Cytek Biosciences, SD Biosensor, The Beauty Tech Group and OrthoPediatrics.

Most AngioDynamics public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
IBA Group0.9x0.9x11.9x11.2x
NeuroPace5.6x5.6x(112.7x)(79.6x)
Mesa Laboratories2.7x2.7x10.5x10.5x
Sofwave Medical5.8x-66.4x-
Myriad Genetics0.8x0.8x17.2x17.6x
Japan Lifeline1.4x1.4x5.9x6.1x
Cytek Biosciences1.8x1.8x(546.3x)(68.0x)
SD Biosensor0.8x-(0.8x)-

This data is available for Pro users. Sign up to see all AngioDynamics competitors and their valuation data.

Start Free Trial

Acquisitions by AngioDynamics

AngioDynamics has acquired 2 companies to date.

Last acquisition by AngioDynamics was on October 3rd 2019. AngioDynamics acquired Eximo Medical for $66M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by AngioDynamics

Eximo Medical
RadiaDyne
Description
Eximo Medical is a Caesarea-based Israeli medtech firm developing the CatHI hybrid catheter for endovascular and gastrointestinal tissue ablation. The single-use device combines short-pulse laser fibers with a mechanical cutter to achieve precise resection in atherectomy and polyp removal procedures. Its technology received CE Mark approval in 2021 and targets coronary, peripheral artery, and Barrett's esophagus applications.
RadiaDyne produces medical devices for radiation oncology including brachytherapy applicators, alpha-emitting sources, and hydrogel spacers. The Houston-based company supplies products for prostate, cervical, and breast cancer treatments to hospitals and clinics in the United States. RadiaDyne focuses on precision delivery systems that minimize radiation to healthy tissues while targeting tumors effectively.
HQ CountryIsraelUnited States
HQ City
Rehovot
Houston, TX
Deal Date3 Oct 201913 Sep 2018
Valuation$66M$90M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all AngioDynamics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About AngioDynamics

When was AngioDynamics founded?AngioDynamics was founded in 1992.
Where is AngioDynamics headquartered?AngioDynamics is headquartered in United States.
How many employees does AngioDynamics have?As of today, AngioDynamics has over 675 employees.
Who is the CEO of AngioDynamics?AngioDynamics' CEO is James C. Clemmer.
Is AngioDynamics publicly listed?Yes, AngioDynamics is a public company listed on Nasdaq.
What is the stock symbol of AngioDynamics?AngioDynamics trades under ANGO ticker.
When did AngioDynamics go public?AngioDynamics went public in 2004.
Who are competitors of AngioDynamics?AngioDynamics main competitors include IBA Group, NeuroPace, Mesa Laboratories, Sofwave Medical, Myriad Genetics, Japan Lifeline, Cytek Biosciences, SD Biosensor, The Beauty Tech Group, OrthoPediatrics.
What is the current market cap of AngioDynamics?AngioDynamics' current market cap is $558M.
What is the current revenue of AngioDynamics?AngioDynamics' last 12 months revenue is $322M.
What is the current revenue growth of AngioDynamics?AngioDynamics revenue growth (NTM/LTM) is 5%.
What is the current EV/Revenue multiple of AngioDynamics?Current revenue multiple of AngioDynamics is 1.6x.
What is the current EBITDA of AngioDynamics?AngioDynamics' last 12 months EBITDA is $18M.
What is AngioDynamics' EBITDA margin?AngioDynamics' last 12 months EBITDA margin is 5%.
What is the current EV/EBITDA multiple of AngioDynamics?Current EBITDA multiple of AngioDynamics is 29.4x.
How many companies AngioDynamics has acquired to date?As of July 2026, AngioDynamics has acquired 2 companies.
What was the largest acquisition by AngioDynamics?$90M acquisition of RadiaDyne on 13th September 2018 was the largest M&A AngioDynamics has done to date.
What companies AngioDynamics acquired?AngioDynamics acquired RadiaDyne and Eximo Medical.
In how many companies AngioDynamics has invested to date?AngioDynamics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to AngioDynamics

Lists including AngioDynamics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial